520 East 70th Street, Starr Pavilion, 3rd Floor
New York, NY 10065
P: 646-962-2700 | F: (212) 746-6645
The Leukemia and Bone Marrow Failure Program at NewYork-Presbyterian Hospital and Weill Cornell Medicine is a comprehensive program with nationally and internationally recognized specialists who treat malignant bone marrow diseases. These include acute and chronic leukemias, such as acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), as well as other, rare types of leukemia including myelodysplastic syndrome and myeloproliferative disorders. Our expert team is also dedicated to treating bone marrow failure.
The Weill Cornell Leukemia Program uses a multidisciplinary approach to provide world-class clinical care in collaboration with our colleagues specializing in the treatment of lymphoma, myeloma, and other blood disorders. We view each person as an individual, and our emphasis on providing highly personalized, individual care ensures that each treatment plan is designed to meet the unique needs of each of our patients and their families. A diagnosis of leukemia or bone marrow failure can affect your whole body physically and emotionally, so we have developed an outstanding team that includes specialists in infectious diseases, geriatrics, gastroenterology, cardiology, nephrology, neurology, pulmonary and critical care medicine, psychiatry, social work, nutrition and other supportive services.
Our Approach to Care
Unlike other institutions, NewYork-Presbyterian Hospital and Weill Cornell Medicine offer a collaborative approach to medicine that provides comprehensive care in conjunction with the most innovative, cutting-edge medical treatments for blood cancer patients. This enables our patients to receive the best possible treatment outcomes. Additionally, the Leukemia Program leads and participates in a wide variety of clinical trials, allowing eligible patients to gain access to new research treatments before they become available to the public.
Specifically, the Leukemia Program offers patients the following:
- Close collaboration with comprehensive bone marrow and stem cell transplantation program
- Access to cutting-edge clinical trials involving newly developed drugs, biological therapies and antibodies
- Specialized in-patient and out-patient units with dedicated and highly trained staff experienced in the needs of our patients
- Extensive collaborations with world-renowned translational scientists, who have specific expertise in leukemia stem cells, genomics and epigenetics
- Specialized focus on clinical trials targeting leukemia stem cells, both at the time of diagnosis, as well as to target and eradicate left-over leukemia stem cells in patients already in remission
In addition to treating patients, all of our doctors serve as academic physicians at Weill Cornell Medicine. Each physician also serves as a principal investigator of one or more clinical trials, and some serve as authors and consultants for protocols still in development. Because of this experience and expertise, many of our doctors have earned the reputation as pioneers in the field. Further, our doctors are known for their collaborative efforts with other top-tier medical centers across the country, which allows us to work together to remain at the forefront of cutting-edge research and therapies for our patients.
Treatment and Clinical Trials
The Leukemia Program not only offers patients standard treatments in a supportive environment, but our program also has a significant focus on treating leukemia and bone marrow failure using the most promising new treatments through clinical trials. Clinical trials are important to improve outcomes and offer new treatment options before they are available commercially. At Weill Cornell Medicine, we conduct numerous clinical studies for nearly all types of leukemia, whether you’re newly diagnosed or have a previously treated blood cancer. These clinical trials include first-line treatments, as well as therapies for refractory or relapsed leukemia.
We specialize in novel therapeutic and diagnostic approaches, including:
- Targeted therapies
- Oral therapies
- Radiation therapy
- Biological immunotherapy – using the body’s immune system to fight cancer.
- Blood transfusion (red blood cells, platelets)
- Medications to prevent or treat damage to other systems of the body caused by leukemia treatment
- Splenectomy – surgery to remove the spleen
- Stem cell or bone marrow transplantation
In addition, researchers within the Leukemia Program are actively working on developing new diagnostic technologies that will allow our doctors to detect minor changes in both the simple and complex mutations often seen in blood cancers. By developing these technologies here at Weill Cornell Medical Center, advances become immediately and exclusively available to our patients, enabling our physicians to carry out detailed monitoring of disease progression and tumor evolution.
Our Scientific Collaborations
In addition to clinical excellence, the Leukemia Program is known for its extensive translational research program. The Program collaborates with several Cornell scientists considered leaders in the field, including Drs. Monica Guzman, Duane Hassane, Joseph Scandura, and Ari Melnick. In addition to developing innovative clinical programs, we strive to understand and correlate the underlying disease process in each of our patients through our close collaboration with research scientists. Each of our scientists have a unique research focus in leukemia, and it is through active collaboration that their work has been successful in yielding better therapeutic approaches to treating blood cancers.
In collaboration with your referring physician, we are always available to offer a second opinion in the form of consultation with one of our specialists.
Why Choose Us?
People who have been diagnosed with leukemia or bone marrow failure in New York City, the Tri-State area and around the world come to the Weill Cornell Leukemia Program because we provide supportive, comprehensive care alongside the most cutting-edge, breakthrough medical treatments. We offer a cohesive approach to care, bringing together specialists from other disciplines, as well as scientists working in research labs to develop the newest treatments. This approach enables our patients to receive the best possible outcomes. Additionally, we are committed to moving the field forward through medical advancements with the potential to alleviate future suffering from leukemia.
Learn more about our team, our approach and our treatment offerings by visiting: www.cornellleukemia.com
To learn more about CRUSH!!MDS and the research efforts of the MDS Clinical Research Consortium, an alliance between six of the nation's leading institutions dedicated to advancing treatments and improving outcomes for patients with MDS, click here.